Key Takeaways
- A brutal quarter, but the worst is over: Domestic revenue fell ~15% and exports slumped 45-50% YoY as a long August dry spell crushed pesticide consumption just as the company finished burning off high-cost inventory. Management says input costs and finished-product prices have now stabilized.
- High-cost inventory consumed, margins rebounding: The company liquidated all high-cost inventory carried from March 2023 by July, with the profit-margin hit shrinking from 12-15% in Q1 to 1.5% by end-September. Q2 gross margins improved materially over Q1.
- New products are the growth thesis: Six products launched in H1, with Promalin, Tembotrione and Glufosinate among them. Management is "very, very confident" in early distributor feedback, though new products will contribute only 1-2% of revenue in their first full year.
- Two new plants started, a third site in the pipeline: Bhavnagar and Tarapur projects began commercial production, with revenue expected this fiscal year and a major ramp-up from FY25. A new Dahej site is awaiting environmental clearance, with INR300 crores of capex planned over two to three years.
- What to watch next quarter: Whether the second-half demand recovery materializes as promised, the pace of margin normalization toward the 19-20% EBITDA target, and any concrete revenue from the five-molecule capex project targeting INR200-220 crores at peak.
The Quarter's Damage: Weather, Inventory & Price
- A dry spell broke the season: An "unbelievable dry spell in the month of August" ruined the customary agriculture timetable, reducing pest and fungal infestations and leading to a noticeable decrease in pesticide applications and consumption across key Indian regions.
- Domestic revenue split: The ~15% domestic decline in H1 broke down as roughly 3% from price and 12% from volume, with Glyphosate prices down 25-30% even as volumes rose ~5%.
- Export collapse: Exports declined 45-50% YoY, with roughly 20% from price and 25-30% from volumes, driven by LatAm demand weakness, destocking by global manufacturers, and low-priced Chinese supply.
- High-cost inventory consumed: The company carried high-cost inventory into the year, causing a profit-margin loss of 12-15% in Q1. That impact shrank to 8% in July, 5% in August, and 1.5% by end-September, with the company back to normal profit lines from August.
- Specialty held up better: While generic prices dropped 15-20% across the board, the specialty portfolio saw only a 3% price decline versus FY22-23, though specialty faced relatively higher volume degrowth because of reduced overall agrochemical consumption.
- Trade sentiment cautious: Distributors avoided stocking in April-May as they traditionally do, buying only hand-to-mouth because prices were dropping weekly or monthly.
Chetan Shah: "we experienced an unbelievable dry spell in the month of August, which ruined the entire planning and entire agrochemical consumption."
Margin Mechanics: The Hit and the Recovery
- Operating leverage was the culprit: The EBITDA margin decline was primarily on account of reduced operating leverage, not structural cost problems. Fixed costs have been structurally reduced from ~19-20% of revenue pre-integration to ~12-13% today.
- Sequential improvement underway: Q2 gross profit margins were much better than Q1 as high-cost inventories were exhausted, input prices stabilized, and finished-product prices also stabilized.
- Cost reduction delivered: Other expenses excluding ERE fell by INR15 crores in H1; overall other expenses excluding ERE were down INR50 crores.
- Wage cost headwind: The Gujarat state government imposed a drastic ~25% wage revision, affecting four of the company's five plants. This is a one-off step-up in the first year but will continue as a permanent cost increase.
- Margin target: Management aims to bring EBITDA margins back to around 19-20% in FY25, confident about maintaining and even improving margins a little bit with input prices expected stable till January.
Chetan Shah: "We continue to be confident about this kind of profitability levels in the medium to long term. But in the current year, because of challenging environment and situation, we have taken a little bit of a hit."
New Product Engine: Launches, Feedback & Ramp-Up
- Six products launched in H1: Three herbicides, one insecticide and two fungicides, including Korko, Ambit, Derecho, CuFlow and Rumpus, receiving positive feedback from trade and farmers.
- Promalin: Launched in March for the apple season ending April 15, 95% of the quantity was sold. Bad weather in Himachal Pradesh and Jammu and Kashmir prevented seeing actual product performance; the next season starts toward Q4.
- Tembotrione: A small pilot launch in July for corn; the season did not go well and the product needs to scale up next year.
- Glufosinate: Launched in a small geography to avoid cannibalizing Glyphosate.
- Rumpus/CuFlow fungicide: Limited launch in August with good acceptance.
- Sumi Blue Diamond: A patented PGR for rice, gaining good traction in South India.
- First-year contribution modest: New products may contribute only 1-2% of revenue in their first full year, then pick up over time.
- Farmer outreach: The company directly reached approximately 0.44 crore-plus farmers and 40,000 dealers.
Chetan Shah: "we are very, very confident about these products. And I mean just to give you an example. We had a recent meeting down South, and the feedback that we received from the distributors and the farmers was overwhelming on this new introduction."
Capex Projects: Bhavnagar, Tarapur & Dahej
- Bhavnagar: Commenced production for a global proprietary product, expected to generate some revenue in FY24 with a major ramp-up from FY25.
- Tarapur: Involves multiple EHD products, started commercial production recently, also expected to contribute revenue this fiscal year.
- Five-molecule capex (INR120 crores): No revenue generated yet from commercial production. Some shipments and revenue expected in H2 of the current year. Management targets 80-100% utilization in FY25, with peak potential of INR200-220 crores.
- Dahej site: Land available, initial approval under process, environmental clearance applications submitted. Expecting clearance in FY24, after which the Board will consider various projects in discussion with parent company SCC. Capex of INR300 crores planned over the next two to three years.
- Normalized capex: Ongoing capex at 15% of EBITDA, with incremental project-specific capex to be announced as approved.
- Operating margins on new projects: Expected to be in line with SCIL's current margin for similar products.
Barrix Acquisition & Inorganic Strategy
- Barrix: A small acquisition in the pheromone segment with green technology and R&D capability, complementary to existing businesses. The technology is world-class with potential in India and globally.
- Domestic pheromone market: The company has a small share of the INR400-500 crore market, with potential to take a leadership position. The market is expected to grow two to three times in the next four to five years.
- Global expansion: Products not requiring registration can be capitalized very quickly; those requiring registration may take longer. Management expects to start seeing significant movement in the next two to three years, though export growth will not be immediate.
- Acquisition preference: The company is looking at further opportunities but prefers smaller and niche segments over a very large company at a very high valuation.
- Parent-company talks: Discussions to bring IT chemicals, pharmaceuticals and other business divisions from the parent into India are ongoing but not forcefully pushed this year due to focus on the existing business and Barrix integration.
Kunal Mittal: "So, I think we are looking at opportunities, I think, as we have mentioned this Barrix that we've announced. So, our preference will be for smaller and niche segments instead of acquiring a very, very large company and at a very, very high valuation."
Demand Outlook: Cautious Optimism for H2, Real Normalcy in FY25
- Global indications positive: Management says global demand indications are "extremely good" for the second half, but cautions that actual business will be taken month-by-month and conditions can change.
- Export recovery partial: Second-half exports will recover but not fully. Improvement is expected in Q3 and Q4, but a real return to FY22-23 volumes will go into the next financial year.
- Domestic normalization: Assuming stable prices and a normal consumption season next year, newly launched products should help growth return to normalcy. The industry historically averages 8-10% growth in a normal year with stable prices.
- Global manufacturers: Expected to resume normalized activities soon, with exports from India to Latin America and other global markets returning to normalized levels in the next few quarters.
- Price stability returning: Price stability is coming back to normal in the domestic market, with prices stable for the last couple of months.
- China situation: Prices spiked in late 2022 for no apparent reason, then fell at a similar rate. Prices have now stabilized and availability of materials is not a problem. In management's personal view, prices have bottomed out.
Chetan Shah: "I would say that cautiously if one wants to approach this subject, I think up to Q4 we may see better prospect than the Q1 and Q2. But a real normalcy should come by the first quarter of '24-'25."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | Target around 19-20% | FY25 |
| Five-molecule capex utilization | 80% to 100% of potential (INR200-220 crores peak) | FY25 |
| Bhavnagar & Tarapur ramp-up | Major revenue contribution | FY25 |
| Dahej environmental clearance | Approval expected | FY24 |
| Dahej capex | INR300 crores | Next two to three years |
| Export volume normalization | Return to FY22-23 volumes | Next financial year |
| Domestic growth normalization | Normal consumption season, stable prices, new products contribute | FY25 |
| Promalin next season | Sales from Q4 onwards | Q4 FY24 |
| Glyphosate government hearing | Company and industry objecting to proposal | December 7 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹903 cr, compared to ₹1,121 cr in Q2 FY23 |
| Gross margin | 38.4%, compared to 31.1% in Q1 FY24, sequential improvement |
| EBITDA | ₹188 cr, compared to ₹278 cr in Q2 FY23 |
| EBITDA margin | 20.8%, compared to 24.8% in Q2 FY23 |
| Profit after tax | ₹143 cr, compared to ₹201 cr in Q2 FY23 |
| PAT margin | 15.9%, compared to 18% in Q2 FY23 |
| H1 FY24 revenue | ₹1,628 cr, compared to ₹2,106 cr in H1 FY23 |
| H1 FY24 domestic revenue share | 89% of overall revenues, export contributing the rest |
| H1 FY24 insecticides share | 40% of total revenue |
| H1 FY24 export revenue share | 11%, down from approximately 19% in H1 FY23 |
| H1 FY24 EBITDA | ₹269 cr, compared to ₹466 cr in H1 FY23 |
| H1 FY24 EBITDA margin | 16.5%, compared to 22.1% in H1 FY23 |
| H1 FY24 profit after tax | ₹205 cr, compared to ₹340 cr in H1 FY23 |
| Net working capital cycle | 70 days, reduction of 24 days as on September 2023 compared to June 2023 and September 2022 |
| H1 FY24 collections | ₹2,000 cr against sales of ₹1,628 cr |
| Domestic business degrowth in Q2 | ~10% compared to Q2 FY23 |
| Domestic volume decline in H1 | ~12% (per an analyst's math), with ~3% attributed to price out of ~15% total domestic decline |
| Export decline in H1 | 45% to 50% total decline, roughly 20% from price and 25% to 30% from volumes |
| Glyphosate volume growth in H1 | 5% increase, prices dropped 25% to 30% |
| Specialty product portfolio value decline | 3% lower prices compared to FY23 |
| Animal Nutrition volume growth in H1 | 31% increase, prices down 38% YoY |
| High-cost inventory profit margin impact | 12% to 15% lost in Q1, declining to ~1.5% by end of September |
| Farmers reached | 0.44 crore-plus farmers and 40,000 dealers |
| Distribution network | 15,000 direct distributors and 60 depots |
| Portfolio brands | 200-plus agrochemical brands, including 20-plus mega brands |
| New products launched in H1 | 6 products: three herbicides, one insecticide, two fungicides |
| Capex guidance | 15% of EBITDA normalized capex for next year |
| Dahej initial capex | ₹300 cr over next two to three years |
| Pheromone segment market size | ₹400 cr to ₹500 cr currently, expected to double or triple in four to five years |